Efficacy of combinations of difluoromethylornithine and bleomycin in a mouse model of central nervous system African trypanosomiasis.
DL-alpha-Difluoromethylornithine, a polyamine biosynthesis inhibitor, and bleomycin, a currently used antineoplastic agent, have each previously been shown to be curative for acute short-term infections of mice with Trypanosoma brucei brucei, an African trypanosome closely related to those that cause the human disease African sleeping sickness. These agents were tested singly and in combination in a previously described mouse model of sleeping sickness with demonstrable brain involvement. The original model is extended by using two additional strains of outbred mice and by demonstrating that melarsoprol, an arsenical and currently the only drug used for human African trypanosomiasis involving the brain, was also curative for these brain infections. Neither difluoromethylornithine nor bleomycin alone was curative for the brain infections; however, many combinations of the two drugs were found to be 100% curative with no evidence of immediate toxicity.
D000818:Animals; D001761:Bleomycin / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D000518:Eflornithine; D005260:Female; D008297:Male; D051379:Mice; D009952:Ornithine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013095:Spermidine / Q000494:pharmacology; D013096:Spermine / Q000494:pharmacology; D014344:Trypanocidal Agents; D014353:Trypanosomiasis, African / Q000188:drug therapy*
D014344:Trypanocidal Agents; D001761:Bleomycin; D013096:Spermine; D009952:Ornithine; D013095:Spermidine; D000518:Eflornithine